Sleep More, Stress Less: 90-Day Trial of Neuralli Mood

NCT07717385 | Recruiting

• 1 other identifier: EFF-NM-90D-2026-01
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This decentralized, single-arm study evaluates the effects of 90 days of daily Neuralli Mood supplementation on perceived stress, sleep disturbance, mood, anxiety, depressive symptoms, happiness, and occupational burnout in adults experiencing stress or occasional sleep disruption. Participants serve as their own controls, completing validated self-report measures before beginning supplementation and again after the 90-day intervention, with safety and adherence check-ins during the study.

Conditions

Psychological Stress; Sleep Disturbance; Anxiety Symptoms; Depressive Symptoms; Occupational Burnout

Keywords

Neuralli Mood; Probiotic; Postbiotic; Psychobiotic; Gut-brain axis; Lactiplantibacillus plantarum PS128; Lacticaseibacillus paracasei PS23; Stress; Sleep; Burnout; Citizen science

Outcome Measures

Primary Outcomes (2)

• Change in Depression Anxiety and Stress Scales-21 Stress Subscale Score

  Change from baseline in the Stress subscale score of the Depression Anxiety and Stress Scales-21. Higher scores (maximum score of 42) represent greater severity of stress symptoms. (Minimum score of 0).

  Baseline before the first dose and end of the 90-day supplementation period

• Change in PROMIS Sleep Disturbance Score

  Change from baseline in the PROMIS Sleep Disturbance score. Higher scores (Maximum 40) represent greater sleep disturbance. Lower (Minimum 8) represent lower sleep disturbance.

  Baseline before the first dose and end of the 90-day supplementation period

Secondary Outcomes (5)

• Change in Depression Anxiety and Stress Scales-21 Anxiety Subscale Score

  Baseline before the first dose and end of the 90-day supplementation period

• Change in Depression Anxiety and Stress Scales-21 Depression Subscale Score

  Baseline before the first dose and end of the 90-day supplementation period

• Change in Oxford Happiness Questionnaire Score

  Baseline before the first dose and end of the 90-day supplementation period

• Change in Burnout Assessment Survey Score

  Baseline before the first dose and end of the 90-day supplementation period

• Number of Participants With Treatment-Emergent Adverse Events

  From the first dose through completion of the 90-day supplementation period

Study Arms (1)

Neuralli Mood Supplementation

EXPERIMENTAL

Participants take two capsules of Neuralli Mood once daily, with or without food, at a consistent time for 90 days and complete scheduled study assessments and safety check-ins.

Dietary Supplement: Neuralli Mood

Interventions

Neuralli Mood DIETARY_SUPPLEMENT

Two acid-resistant capsules taken once daily for 90 days. Each daily dose contains 30 billion CFU of L. plantarum PS128 and 20 billion heat-treated cells of L. paracasei PS23. Other ingredients include microcrystalline cellulose, hypromellose, pectin, glycerol, silica, and magnesium stearate.

Also known as: Bened Life Neuralli Mood

Neuralli Mood Supplementation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older and able to provide informed consent.
• Generally healthy adult experiencing stress, occasional sleep disruption, low mood, anxiety symptoms, or work-related burnout.
• Willing and able to take two capsules of Neuralli Mood daily for 90 days.
• Willing and able to complete electronic baseline, follow-up, adherence, and safety assessments.
• Has reliable access to the internet and an email-enabled device.

You may not qualify if:

• Pregnant or nursing.
• Known allergy or hypersensitivity to Neuralli Mood, probiotics, or any product ingredient.
• Severe or unstable gastrointestinal disease, including a condition for which probiotic use may be inappropriate.
• Immunocompromised status or current immunosuppressive therapy.
• Severe or unstable mood disorder, acute psychiatric symptoms, or a current risk of harm to self or others.
• A clinically significant sleep disorder for which participation or changes in symptoms should be managed by a healthcare professional.
• Cognitive impairment or another condition that prevents informed consent or reliable completion of study procedures.
• History of a severe allergic reaction when the investigator determines probiotic use may present an unacceptable risk.
• Use of a medication or presence of a medical condition for which a healthcare professional advises against probiotic supplementation.
• Any other circumstance that, in the investigator's judgment, makes participation inappropriate or unsafe.

Sponsors & Collaborators

• Efforia, Inc: lead
• Bened Life: collaborator

Study Sites (1)

Efforia - Decentralized United States Study

New York, New York, 10003, United States

RECRUITING

MeSH Terms

Conditions

Stress, Psychological; Parasomnias; Anxiety Disorders; Depression; Burnout, Professional; Burnout, Psychological

Condition Hierarchy (Ancestors)

Behavioral Symptoms; Behavior; Sleep Wake Disorders; Nervous System Diseases; Mental Disorders; Occupational Stress; Occupational Diseases

Study Officials

• Matthew Amsden

  Efforia, Inc

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Matthew Amsden

CONTACT

+13232844626; help@efforia.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: Participants and investigators know that Neuralli Mood is being administered. No placebo or blinded comparator is used.
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: All participants complete baseline assessments, take two capsules of Neuralli Mood daily for 90 days, complete scheduled adherence and safety check-ins, and repeat the outcome assessments at the end of the supplementation period. Each participant serves as his or her own control.

Study Record Dates

• First Submitted: July 13, 2026
• First Posted: July 21, 2026
• Study Start: June 30, 2026
• Primary Completion (Estimated): September 28, 2027
• Study Completion (Estimated): September 28, 2027
• Last Updated: July 21, 2026

Record last verified: 2026-07

Locations

US (1)